Clinical Trial Update: A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating drug tolerant persister (DTP) to preoperative brigatinib in resectable non-small cell lung cancer with ALK fusions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: Yonsei University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN